| Product Name | NebuSelect™ Recombinant Human CXCL4L1, hFc-tag |
|---|---|
| Catalog Number | NBL-241813 |
| Alias/Synonyms | CXCL4L1 |
| Appearance | see COA |
| Molecule Weight | Phe31-Ser104 |
| CAS | N/A |
| Solubility | Water Soluble |
| Storage | Short term 4℃; Long term -20℃. |
| Shelf Life | 2 years |
| Additional info 1 | P10720 |
| Additional info 2 |
| Catalog Numbe | Size | Price | Inventory Level | |
| NBL-241813-100ug | 100ug | Inquire | Inquire | |
| NBL-241813-1mg | 1mg | Inquire | Inquire | |
| NBL-241813-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human CXCL4L1, hFc-tag
Catalog#:
NBL-241813
Description:
NebuSelect™ Recombinant Human CXCL4L1, hFc-tag(Cat#NBL-241813) is expressed in HEK293 with hFc tag at the C-Terminus.It contains Phe31-Ser104.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 35.01 kDa. Due to glycosylation, the protein migrates to 43-48 kDa based on Bis-Tris PAGE result.
Target Name:
CXCL4L1
Target Information:
Platelet factor-4 (CXCL4/PF-4) was the first chemokine shown to inhibit angiogenesis. CXCL4L1/PF-4var, recently isolated from thrombin-stimulated platelets, differing from authentic CXCL4/PF-4 in three carboxy-terminally located amino acids, was found to be more potent than CXCL4/PF-4 in inhibiting angiogenesis and tumor growth. Both glycosaminoglycans (GAG) and CXCR3 are implicated in the activities of the PF-4 variants.
Amino Acid Sequence:
Phe31-Ser104
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.